Journal of Neuro-Oncology

, Volume 24, Issue 3, pp 299–301 | Cite as

Response of brain metastases from breast cancer to megestrol acetate: A case report

  • David J. Stewart
  • Simone Dahrouge
Clinical Study


A 56 year old women was treated with megestrol acetate (Megace) 40 mg p.o. q.i.d. for her cerebellar metastasis of primary adenocarcinoma of the breast. She had previously undergone two surgical resections of her brain metastasis, and a course of radiotherapy. After failing to tolerate tamoxifen therapy, she received Megace, with marked improvement in her cerebellar tumor on CT scans. Despite good control of her brain tumor with Megace, she developed progressive neurological symptoms thought to be due to meningeal carcinomatosis, and died two years after initiating Megace therapy. We conclude that Megace could potentially be beneficial in some patients with brain metastases from adenocarcinoma of the breast.

Key words

megace brain metastases breast cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tsukada Y, Fouad A, Pickren J, Lane W: Central nervous system metastasis from breast carcinoma: Autopsy study. Cancer 52: 2349–2354, 1983PubMedGoogle Scholar
  2. 2.
    Cairncross JG, Kim J-H, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7: 529–541, 1980PubMedGoogle Scholar
  3. 3.
    Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain tumors. The ‘blood-brain barrier’ is not a factor. Arch Neurol 34: 523–526, 1977PubMedGoogle Scholar
  4. 4.
    Stewart DJ: A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol 20: 121–139, 1994Google Scholar
  5. 5.
    Rosner D, Takuma N, Lane WW: Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58: 832–839, 1986PubMedGoogle Scholar
  6. 6.
    Hildebrand J, Brihaye J, Wagenknecht L, Michel J, Kenis Y: Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Europ J Cancer 11: 585–587, 1975Google Scholar
  7. 7.
    Lester SG, Morphis JG, Hornback NB, Williams SD, Einhorn LH: Brain metastases and testicular tumors: Need for aggressive therapy. J Clin Oncol 2: 1397–1403, 1984PubMedGoogle Scholar
  8. 8.
    Carey RW, Davis JM, Zervas NT: Tamoxifen-induced regression of cerebral metastases in breast carcinomas. Can Treat Rep 65: 793–795, 1981Google Scholar
  9. 9.
    Hansen SB, Galsgard H, von Eyben FE, Westergaard-Nielsen V, Wolf-Jensen J: Tamoxifen for brain metastases from breast cancer. Ann Neurol 20: 544, 1986Google Scholar
  10. 10.
    Pors H, von Eyben Fe, Sorensen OS, Larsen M: Longterm remission of multiple brain metastases with tamoxifen. J Neuro-Oncol 10: 173–177, 1991Google Scholar
  11. 11.
    van der Gaast A, Alexieva-Figusch J, Vecht C, Verweij J, Stoter G: Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate. Am J Clin Oncol 13 (6): 507–509, 1990PubMedGoogle Scholar
  12. 12.
    Lundgren S: Progestins in breast cancer treatment. Acta Oncol 31: 709–722, 1992PubMedGoogle Scholar
  13. 13.
    Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang K-P, Romsdahl MM, Martin R: Estrogen receptor: A prognostic factor in breast cancer. Cancer 47: 554–560, 1981PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • David J. Stewart
    • 1
  • Simone Dahrouge
    • 1
  1. 1.Ontario Cancer Treatment and Research FoundationOttawa Regional Cancer Centre and the University of Ottawa Faculty of MedicineCanada

Personalised recommendations